ArticleMethods in molecular biology (Clifton, N.J.)2026
Phage-Assisted Continuous Selection of Bioactive Cyclic Peptides.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclic peptides (CPs) are a class of molecules that can display various biological activities and have been utilized extensively as a source for therapeutic leads and chemical probes. Recently, a strategy inspired by phage-assisted continuous evolution (PACE) was established for high-throughput discovery of CP protein aggregation inhibitors. This method leverages customizable genetic circuits to link desired activities of CP to expression of M13 phage minor coat protein pIII, allowing enrichment of active CP sequences by serial phage propagations through E. coli host cells. Compared with existing strategies, this approach enables rapid cellular selection of bioactive CPs while requiring only standard molecular biology techniques and equipment. In this chapter, we provide a comprehensive protocol for applying this strategy to select CP inhibitors against aggregation-prone proteins of interest. Details and procedures covered in this protocol can also provide a foundation for experimental design to discover CPs possessing other bioactivities.
Indexed as
Identifiers
42681184What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.